{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.9","upperLimit":"20.6","value":"14.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Time from start of study treatment to disease progression per independent review group or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"MEDIAN","populationDescription":"Intention to treat","reportingStatus":"POSTED","timeFrame":"up to approximately 3 years","title":"Progression-free Survival by Kaplan-Meier Analysis","type":"SECONDARY","unitOfMeasure":"months"}